Search
Kalaris Therapeutics Inc
KLRSAdd to Watchlist
3.220USD
-0.025-0.77%
Market hours 09/22, 12:07（ET）
76.65MMarket Cap
LossP/E TTM
Kalaris Therapeutics Inc (KLRS) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Kalaris Therapeutics Inc in the past month.
Buy
4 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
17.667USD+452.08%
KLRS Analyst Recommendation Trends
In the current month, KLRS has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KLRS average Analyst price target in the last month is 17.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
3
3
3
3
3
3
4
3
3
2
2
2
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
9
8
7
6
6
6
KLRS Analyst Rating for Peer Comparison
Updated: Sep 21, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, KLRS EPS is projected to reach -0.509 in FY2026Q3, following reported EPS of -0.484 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.53
-0.52
-0.49
-0.51
-0.53
Actual
-0.51
-0.46
-0.48
--
--
Surprise
+3.31%
+12.53%
+2.25%
--
--
FAQs
What is Kalaris Therapeutics Inc's price target?
Analysts forecast that Kalaris Therapeutics Inc's price target is USD 17.67, with the highest forecast at USD 25.00 and the lowest forecast at USD 7.00.
How have Kalaris Therapeutics IncKLRS's recent earnings per share performed?
The market expectation was USD -0.48, while Kalaris Therapeutics IncKLRS's earnings per share (EPS) for the previous quarter was USD -0.46. EPS for the next quarter is expected at USD -0.51.
What is the analyst rating for Kalaris Therapeutics Inc?
Based on the ratings of Kalaris Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.